Zobrazeno 1 - 10
of 242
pro vyhledávání: '"Kast RE"'
Publikováno v:
Breast Cancer: Targets and Therapy, Vol Volume 9, Pp 495-514 (2017)
Richard E Kast,1 Nicolas Skuli,2 Samuel Cos,3 Georg Karpel-Massler,4 Yusuke Shiozawa,5 Ran Goshen,6 Marc-Eric Halatsch4 1IIAIGC Study Center, Burlington, VT, USA; 2INSERM, Centre de Recherches en Cancérologie de Toulouse – CRCT, UMR1037 Inserm/Uni
Externí odkaz:
https://doaj.org/article/4e6e679f64db42edab80fb791718a624
Autor:
Anthonymuthu, J, Golla, C, Dwucet, A, Pruss, M, Hlavac, M, Kast, RE, Wirtz, CR, Halatsch, ME, Siegelin, MD, Westhoff, MA, Karpel-Massler, G
Publikováno v:
71. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), 9. Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie; 20200621-20200624; sine loco [digital]; DOCV082 /20200626/
Objective: Vacquinol represents an experimental anti-malaria drug which has been previously described to provide anti-glioma activity.The purpose of this study was to examine whether treatment with vacquinol would enhance the pro-apoptotic reprogramm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87c1519a15566c94ed3d413a73a0cea1
Autor:
Halatsch, ME, Kast, RE, Karpel-Massler, G, Schmitz, B, Zolk, O, Bullinger, L, Mayer-Steinacker, R, Maier, L, Scheuerle, A, Mayer, B, Schmidt, C, Zeiler, K, Elshaer, Z, Awad, F, Panther, P, Schmelzle, B, Beckers, K, Siegelin, MD, Westhoff, MA, Wirtz, CR, Bouche, G, Heiland, T
Publikováno v:
70. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Skandinavischen Gesellschaft für Neurochirurgie; 20190512-20190515; Würzburg; DOCP082 /20190508/
Objective: Despite refinements of neurosurgical techniques and emerging adjuvant therapies, patients with recurrent glioblastoma continue to face a dismal prognosis. We report interim results of a prospective clinical trial (NCT02770378) evaluating a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dc1bde8883f80fbfa52a1b314dd663d
Publikováno v:
70. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Skandinavischen Gesellschaft für Neurochirurgie; 20190512-20190515; Würzburg; DOCP052 /20190508/
Objective: Drug repurposing is a strategy to safely accelerate the clinical application of therapeutics that provide anti-cancer activity. CUSP9* represents such a therapeutic regime which includes nine repurposed drugs along with low-dose metronomic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a65bffeffb3706e48d73c912dcf226f
Publikováno v:
OncoTargets and Therapy, Vol 2016, Iss Issue 1, Pp 2535-2545 (2016)
Michael E Salacz,1,2 Richard E Kast,3 Najmaldin Saki,4 Ansgar Brüning,5 Georg Karpel-Massler,6 Marc-Eric Halatsch6 1Department of Internal Medicine, 2Department of Neurosurgery, University of Kansas, Kansas City, KS, USA; 3IIAIGC Study Center, Burli
Publikováno v:
British Journal of Pharmacology. Nov2011, Vol. 164 Issue 5, p1393-1396. 4p.
Autor:
Kast RE (AUTHOR)
Publikováno v:
Journal of Clinical Pharmacy & Therapeutics. Dec2010, Vol. 35 Issue 6, p657-663. 7p.
Publikováno v:
British Journal of Pharmacology. Oct2010, Vol. 161 Issue 3, p481-487. 7p.
Autor:
Karpel-Massler, G, Kast, RE, Westhoff, MA, Dwucet, A, Welscher, N, Nonnenmacher, L, Hlavac, M, Siegelin, MD, Wirtz, CR, Debatin, KM, Halatsch, ME
Publikováno v:
66. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC); 20150607-20150610; Karlsruhe; DOCMI.09.06 /20150602/
Objective: The continuously poor prognosis of patients with glioblastoma urges the discovery of more effective therapeutics. Repurposing of already existing drugs involves the clinical application of old agents with previously not known or not utiliz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0177359307045af53de3bbc832a111b2
Autor:
Kast Re
Publikováno v:
Molecular Immunology. 40:297-303
Current attempts at active immunization of patients to their adenocarcinomas have heretofore met with a curiously little success. The carrier antigens, viral vector proteins, and other co-administered antigens typically elicit strong cell-mediated or